Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: A retrospective analysis in hypertensive patients of the SMILE-4 study

Journal of Hypertension

Volumn 31, Issue 6, 2013, Pages 1256-1264

  Borghi, Claudio ^a   Ambrosioni, Ettore ^a   Omboni, Stefano ^b   Cicero, Arrigo F G ^a   Bacchelli, Stefano ^a   Esposti, Daniela D ^a   Vinereanu, Dragos ^c   Ambrosio, Giuseppe ^d   Zava, Dario ^e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b ITALIAN INSTITUTE OF TELEMEDICINE   (Italy)

^c University and Emergency Hospital   (Romania)

^d UNIVERSITY OF PERUGIA   (Italy)

^e Instituto Lusofarmaco d'Italia SpA   (Italy)

Author keywords

acetylsalicylic acid; acute myocardial infarction; angiotensin converting enzyme inhibitors; arterial hypertension; left ventricular dysfunction; ramipril; zofenopril

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; RAMIPRIL; TICLOPIDINE; ZOFENOPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EVENING DOSAGE; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIDE EFFECT;

EID: 84877581914     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283605cd8     Document Type: Article

References (46)

1. Lawes CM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease2001. Lancet 2008; 371:1513-1518.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2005; 360:1903-1913; Erratum in: Lancet 2003; 361:1060.
3. Rabkin SW, Mathewson FA, Tate RB. Prognosis after acute myocardial infarction: relation to blood pressure values before infarction in a prospective cardiovascular study. Am J Cardiol 1977; 40:604-610.
4. Herlitz J, Karlson BW, Richter A, Wiklund O, Jablonskiene D, Hjalmarson A. Prognosis in hypertensives with acute myocardial infarction. J Hypertens 1992; 10:1265-1271.
5. Fresco C, Avanzini F, Bosi S, Franzosi MG, Maggioni AP, Santoro L, Bellanti G. Prognostic value of a history of hypertension in 11 483 patients with acute myocardial infarction treated with thrombolysis. GISSI-2 Investigators. Gruppo Italiano per lo Studio della, Sopravvivena nell'Infarto Miocardico. J Hypertens 1996; 14:743-750.
6. Haider AW, Chen L, Larson MG, Evans JC, Chen MH, Levy D. Antecedent hypertension confers increased risk for adverse outcomes after initial myocardial infarction. Hypertension 1997; 30:1020-1024.
7. Chen G, Hemmelgarn B, Alhaider S, Quan H, Campbell N, Rabi D. Meta-analysis of adverse cardiovascular outcomes associated with antecedent hypertension after myocardial infarction. Am J Cardiol 2009; 104:141-147.
8. Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, et al. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension 2008; 51:48-54.
9. Dumaine R, Gibson CM, Murphy SA, Southard M, Ly HQ, McCabe CH, et al., Thrombolysis in Myocardial Infarction (TIMI) Study Group. Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich) 2006; 8:315-322.
10. Bertomeu V, Cabadeacute;s A, Morillas P, Cebrián J, Colomina F, Valencia J, et al. Clinical course of acute myocardial infarction in the hypertensive patient in Eastern Spain: the PRIMVAC registry. Heart Lung 2006; 35:20-26.
11. Abrignani MG, Dominguez LJ, Biondo G, Di Girolamo A, Novo G, Barbagallo M, et al. In-hospital complications of acute myocardial infarction in hypertensive subjects. Am J Hypertens 2005; 18 (2 Pt 1): 165-170.
12. Majahalme SK, Smith DE, Cooper JV, Kline-Rogers E, Mehta RH, Eagle KA, Bisognano JD. Comparison of patients with acute coronary syndrome with and without systemic hypertension. Am J Cardiol 2003; 92:258-263.
13. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23:1190-1201.
14. Willich SN, Müller-Nordhorn J, Kulig M, Binting S, Gohlke H, Hahmann H, et al., PIN Study Group. Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study. Eur Heart J 2001; 22:307-313.
15. Richards AM, Nicholls MG, Troughton RW, Lainchbury JG, Elliott J, Frampton C, et al. Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol 2002; 39:1182-1188.
16. Fretheim A, Odgaard-Jensen J, Broslash;rs O, Madsen S, Njoslash;lstad I, Norheim OF, et al. Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med 2012; 10:33.
17. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al., Task Force on ACE-inhibitors of the European Society of Cardiology. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACEinhibitors of the European Society of Cardiology. Eur Heart J 2004; 25:1454-1470.
18. Borghi C, Bacchelli S, Esposti DD, Bignamini A, Magnani B, Ambrosioni E. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens 1999; 12:665-672.
19. Gustafsson F, Torp-Pedersen C, Koslash;ber L, Hildebrandt P. Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event. J Hypertens 1997; 15:793-798.
20. Spargias K, Ball S, Hall A. The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy. J Hum Hypertens 1999; 13:511-516.
21. Moyeacute; LA, Pfeffer MA, Wun CC, Davis BR, Geltman E, Hayes D, et al. Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study. Eur Heart J 1994; 15 (Suppl.B):2-8.
22. Kostis JB. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens 1995; 8:909-914.
23. Rakugi H, Yu H, Kamitani A, Nakamura Y, Ohishi M, Kamide K, et al. Links between hypertension and myocardial infarction. Am Heart J 1996; 132 (1 Pt 2 Su):213-221.
24. Picariello C, Lazzeri C, Attanà P, Chiostri M, Gensini GF, Valente S. The impact of hypertension on patients with acute coronary syndromes. Int J Hypertens 2011; 2011:563657.
25. Ambrosioni E. Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs 2007; 7:17-24.
26. Przyklenk K, Kloner RA. Cardioprotection' by ACE-inhibitors in acute myocardial ischemia and infarction? Basic Res Cardiol 1993; 88 (Suppl.1):139-154.
27. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 2005; 33:42-54.
28. Borghi C, Bacchelli S, Degli Esposti D. Long-term clinical experience with zofenopril. Expert Rev Cardiovasc Ther 2012; 10:973-982.
29. Borghi C, Ambrosioni E, Novo S, Vinereanu D, Ambrosio G, SMILE-4 Working Party. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol 2012; 35:416-423.
30. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensinconverting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332:80-85.
31. Kenchaiah S, Davis BR, Braunwald E, Rouleau JL, Dagenais GR, Sussex B, et al., Survival, Ventricular Enlargement Trial. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial. Am Heart J 2004; 148:356-364.
32. McDonald KM, Garr M, Carlyle PF, Francis GS, Hauer K, Hunter DW, et al. Relative effects of alpha 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation 1994; 90:3034-3046.
33. McDonald KM, Carlyle PF, Matthews J, Hauer K, Elbers T, Hunter D, Cohn JN. Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition. Trans Assoc Am Physicians 1990; 103:229-235.
34. Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, Liguori A. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148:e5.
35. Cacciatore F, Bruzzese G, Vitale DF, Liguori A, de Nigris F, Fiorito C, et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients. Eur J Clin Pharmacol 2011; 67:877-883.
36. Napoli C, Bruzzese G, Ignarro LJ, Crimi E, de Nigris F, Williams-Ignarro S, et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156:1154.
37. Pasini AF, Garbin U, Nava MC, Stranieri C, Pellegrini M, Boccioletti V, et al. Effect of sulfhydryl and nonsulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20:443-450.
38. Jonas M, Grossman E, Boyko V, Behar S, Hod H, Reicher-Reiss H. Relation of early and one-year outcome after acute myocardial infarction to systemic arterial blood pressure on admission. Am J Cardiol 1999; 84:162-165.
39. Frazier CG, Shah SH, Armstrong PW, Bhapkar MV, McGuire DK, Sadowski Z, et al., SYMPHONY, the Second SYMPHONY Investigators. Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sindrome (SYMPHONY) randomized clinical trials. Am Heart J 2005; 150:1260-1267.
40. El-Menyar A, Zubaid M, Shehab A, Bulbanat B, Albustani N, Alenezi F, et al. Prevalence and impact of cardiovascular risk factors among patients presenting with acute coronary syndrome in the middle East. Clin Cardiol 2011; 34:51-58.
41. Ali WM, Zubaid M, El-Menyar A, Al Mahmeed W, Al-Lawati J, Singh R, et al. The prevalence and outcome of hypertension in patients with acute coronary syndrome in six Middle-Eastern countries. Blood Press 2011; 20:20-26.
42. Takkouche B, Etminan M, Caamaño F, Rochon PA. Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a meta-analysis. Drug Saf 2002; 25:373-378.
43. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensinconverting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368:581-588.
44. Mahé I, Meune C, Diemer M, Caulin C, Bergmann JF. Interaction between aspirin and ACE inhibitors in patients with heart failure. Drug Saf 2001; 24:167-182.
45. Cialdai C, Giuliani S, Valenti C, Tramontana M, Maggi CA. Differences between zofenopril and ramipril, two ACE inhibitors, on cough induced by citric acid in guinea pigs: role of bradykinin and PGE2. Naunyn Schmiedebergs Arch Pharmacol 2010; 382:455-461.
46. Mutolo D, Bongianni F, Evangelista S, Cinelli E, Pantaleo T. Effects of zofenopril and ramipril on cough reflex responses in anesthetized and awake rabbits. J Cardiovasc Pharmacol Ther 2010; 15:384-392.